Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series

Table 1 Patient demographics and clinical characteristics

		n	%
Total		43	100
Age	Median	54	---
Age	Range	19-74	---
Gender	Male	26	60.5
Gender	Female	17	39.5
ECOG PS	0	7	16.3
	1	30	69.8
	2	6	14.0
Histology	Leiomyosarcoma	9	20.9
	Angiosarcoma	6	14.0
	MFH/UPS	5	11.6
	MPNST	5	11.6
	Fibroblastic tumor	4	9.3
	Synovial sarcoma	4	9.3
	Rhabdomyosarcoma	3	7.0
	Liposarcoma	2	4.7
	Tumor of uncertain differentiation	3	7.0
	Desmoplastic small cell tumor	1	2.3
	PEComa	1	2.3
FNCLCC grade	1	3	7.0
	2	6	14.0
	3	13	30.2
	unknown	21	48.8
Primary site	Trunk or retroperitoneum	34	79.1
Primary site	Extremity	9	20.9
Organ involvement	Lung	32	74.4
	Liver	12	27.9
	Bone	17	39.5
Number of prior chemotherapy regimens chemotherapies	1	9	20.9
	2	15	34.9
	≥3	19	44.2
Agents used in prior regimen(s)	Doxorubicin	30	69.8
	Ifosfamide	39	90.7
	Taxane	32	74.4
	Gemcitabine	28	65.1
	Dacarbazine	6	14.0
Cycles of pazopanib treatment	Median	4.8	---
Cycles of pazopanib treatment	Range	1-17	---

ECOG = Eastern Cooperative Oncology Group, PS = performance status, MFH/UPS = malignant fibrous histiocytoma/undifferentiated pleomorphic sarcoma, MPNST = malignant peripheral nerve sheath tumor, PEComa = perivascular epithelioid cell tumor, FNCLCC = French Fédération Nationale des Centres de Lutte Contre le Cancer.

ISSN: 1471-2407